Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.

Publication Type:

Journal Article

Authors:

Persky, Daniel O; Unger, Joseph M; Spier, Catherine M; Stea, Baldassarre; LeBlanc, Michael; McCarty, Matthew J; Rimsza, Lisa M; Fisher, Richard I; Miller, Thomas P

Source:

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 26, Issue 14, p.2258-63 (2008)

Keywords:

2008, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Cyclophosphamide, Disease-Free Survival, Doxorubicin, Female, Humans, Lymphoma, B-Cell, Male, Middle Aged, Neoplasm Staging, Prednisone, Public Health Sciences Division, Vincristine

Abstract:

To evaluate the effect of rituximab in limited-stage diffuse large B-cell lymphoma (DLBCL), we conducted a multicenter phase II trial combining rituximab with three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP) followed by involved-field radiation therapy (IFRT).